Search
Diosmin
go.drugbank.com/drugs/DB08995ApprovedInvestigationalDiosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.[A232890,T840,L33040] … Chronic venous insufficiency is a common condition the western population.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2C9 InhibitorsFludeoxyglucose (18F)
go.drugbank.com/drugs/DB09502ApprovedInvestigationalFludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with
Categories: Compounds used in a research, industrial, or household settingProducts: MON.FDG IV ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADET, MOLTEK FDG IV ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADETN-Acetylmethionine
go.drugbank.com/drugs/DB01646InvestigationalSynonyms: N-Ac-MetMixtures: AZONEFROL-PD PERİTON DİYALİZ ÇÖZELTİSİ, 2000 ML TEKLİ TORBA, AZONEFROL-PD PERİTON DİYALİZ ÇÖZELTİSİ, 2500 ML ÇİFTLİ TORBABisegliptin
go.drugbank.com/drugs/DB06127InvestigationalBisegliptin is a compound for the treatment of type 2 diabetes. … It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion
Categories: DPP-IV InhibitorsGedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigational[L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).
Somapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigationalSomapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency. … [A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersEfbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigationalEfbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration … [L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim
Arotinolol
go.drugbank.com/drugs/DB09204InvestigationalArotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesRiltozinameran
go.drugbank.com/drugs/DB17095ApprovedInvestigationalThe Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … [L43917] Riltozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineage BA.1.
Bleomycin
go.drugbank.com/drugs/DB00290ApprovedInvestigationalIt inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. … A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0).